Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.19
−$0.06 · -1.85%
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Previous close
$3.19
−$0.06 · -1.85%
Pre-market
$3.25
+$0.06 · +1.88%
Sep 11, 6:14 AM ET
Regular session · ET · Market data may be delayed.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Day range
Current $3.19
52-week range
Current $3.19
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
44
Mixed
Risk
62
High Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Day range
Current $3.19
52-week range
Current $3.19
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 40.37M USD | 80M USD | 250.01M USD | 40.91M USD | 37.42M USD |
| Cost of goods sold | 132.27M USD | — | 92.17M USD | 55.76M USD | 73.79M USD |
| Gross profit | −91.9M USD | 80M USD | 157.84M USD | −14.86M USD | −36.37M USD |
| Research and development | 134.67M USD | 127.37M USD | 92.17M USD | 60.76M USD | 73.79M USD |
| Selling, general, and administrative | 36.44M USD | 35.92M USD | 35.82M USD | 30.98M USD | 37.25M USD |
| Operating expenses | 39.94M USD | 163.29M USD | 35.82M USD | 35.98M USD | 37.25M USD |
| Interest income | 10.62M USD | 18.33M USD | 11.72M USD | 1.79M USD | — |
| Depreciation and amortization | 4.06M USD | 4.73M USD | 4.44M USD | 6.19M USD | 5.17M USD |
| Operating income | −131.84M USD | −83.29M USD | 122.01M USD | −50.84M USD | −73.62M USD |
| Net income | −119.72M USD | −65M USD | 132.33M USD | −46.41M USD | −71.2M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$14.40
351.41% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.07M0.00%2.3T USD0.03%$373.24-0.62%
iShares Russell 2000 ETFIWM4.36M0.01%77.55B USD0.19%$287.7-1.01%
Vanguard Extended Market ETFVXF1.86M0.00%93.7B USD0.05%$236.16-1.05%
iShares Russell 2000 Value ETFIWN1.58M0.01%14.28B USD0.24%$218.97-0.68%
iShares Biotechnology ETFIBB1.2M0.01%10.3B USD0.44%$202.64-1.39%
Vanguard Russell 2000 ETFVTWO898.56K0.01%17.4B USD0.06%$116.34-1.00%
iShares Micro-Cap ETFIWC594.97K0.04%1.44B USD0.60%$190.1-1.22%
Fidelity Enhanced Small Cap ETFFESM519.15K0.01%6.49B USD0.28%$46.00-1.18%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
